Latest disclosed round
Series B (extended round)
- Date
- 2021-09-15
- Amount
- USD 125m
- Sector
- Biotech & techbio
- Companies House
- 09272873
Series B
Touchlight
Cell-free synthetic/enzymatic DNA manufacturing platform (dbDNA / mbDNA, 'doggybone DNA') for genetic medicine manufacturing -- mRNA therapeutics, viral vector production, DNA vaccines
VerifiedSeries B (extended round)Hampton, Middlesex (Greater London)
Evidence status
Directory ready
- Identity
- Verified
- Match
- Verified
- Operating status
- active
- Data origins
- Core directory, Live Chris T D1
Capital network
4 linked investors
Bridford Investments LimitedleadDowning (Downing Ventures' first investment in the company)participantNetwork of ultra-high-net-worth individuals, family offices and specialist healthcare investors (not individually named in press)participantNovator Partners (joined for the September 2021 extension)lead
Funding record
2 disclosed rounds
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2021-09-15 | Series B (extended round) | $125m (£92m) aggregate | Bridford Investments Limited, Novator Partners (joined for the September 2021 extension), Network of ultra-high-net-worth individuals, family offices and specialist healthcare investors (not individually named in press) |
| 2014-10-30 | Series A | undisclosed | undisclosed, Downing (Downing Ventures' first investment in the company) |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.